Welcome to our dedicated page for GMRBV SEC filings (Ticker: GMRBV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GMRBV's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GMRBV's regulatory disclosures and financial reporting.
Chiron Real Estate Inc. director and CEO/President Mark Okey Decker Jr reported equity compensation awards in the form of LTIP Units in Chiron Real Estate LP, the company’s operating partnership. He acquired 16,616 LTIP Units and 4,702 LTIP Units, both at a stated price of $0.00 per unit.
According to the award terms, some LTIP Units vest fully on February 24, 2029 subject to continued employment, while another grant vests 50% on February 24, 2026 based on market-based performance criteria as of December 31, 2025 and February 24, 2026, and 50% on February 24, 2027. Once vested and after achieving capital account parity, these LTIP Units may be exchanged for cash or, at the company’s election, for common stock on a one-for-one basis and have no expiration date.
Chiron Real Estate Inc., formerly Global Medical REIT, reported 2025 results, updated its capital strategy and completed a corporate rebrand. For 2025, total revenue was $148.2 million and the company recorded a net loss of $6.9 million, driven in part by $13.0 million of property impairments.
FFO attributable to common stockholders and noncontrolling interest was $57.6 million ($3.97 per share and unit), while Core FFO reached $65.8 million ($4.53 per share and unit). Leverage was 44.4% at December 31, 2025, with $653.9 million of consolidated debt at a 3.74% weighted average interest rate and no maturities in 2026 or 2027.
The board kept the annualized common dividend at $3.00 per share but shifted to monthly payments, declaring $0.25 per share for each of April, May and June 2026. The company invested $7.1 million for a 49% interest in an active adult joint venture and set 2026 Core FFO guidance at $4.30 to $4.45 per share and unit. A key tenant, White Rock Medical Center, filed for Chapter 11, and Chiron carried a $1.4 million net receivable from its support efforts.
Global Medical REIT Inc. reported that director Henry Cole has informed the Board that he intends to step down as a director, effective at the Company’s 2026 Annual Meeting of Stockholders. He will not be nominated for re-election, and his service will end when his current term expires on the date of that meeting.
The Company states that Mr. Cole’s decision to step down is not due to any disagreement with Global Medical REIT Inc. on matters related to its operations, policies, or practices, indicating an orderly and planned board transition rather than a dispute-driven change.
Global Medical REIT Inc. disclosed an insider share purchase by its CEO and President. On 12/05/2025, the reporting person, who also serves as a director, bought 10,000 shares of common stock at a price of $32.51 per share. Following this transaction, the individual directly owned 54,774 shares of Global Medical REIT common stock and indirectly owned 3,404 additional shares through a spouse.
Global Medical REIT Inc. reported that director Ronald Marston has informed the Board that he intends to retire as a director, effective at the company’s 2026 Annual Meeting of Stockholders. He will not stand for re-election, and his service will conclude when his current term expires at that meeting. The company stated that Mr. Marston’s decision to retire is not due to any disagreement with Global Medical REIT regarding its operations, policies, or practices, indicating this is a planned governance transition rather than a response to a specific dispute.